100 Days Mission Ebola Clock: Day 30 (minor update)
The 100 Days Mission (100DM) clock for Bundibugyo ebolavirus started on 18 May 2026, following the World Health Organization’s declaration of the Ebola outbreak in the Democratic Republic of Congo and Uganda as a Public Health Emergency of International Concern (PHEIC). Today we are publishing the Day 30 update on diagnostics, therapeutics, and vaccine availability for Bundibugyo virus.
Leading up to Day 100 on 25 August, IPPS will provide updates every 15 days (alternating between major and minor) on the status and progress of diagnostics, therapeutics, and vaccine development for Bundibugyo virus. The major updates provide detailed deep dives into these medical countermeasures and highlight specific priority actions to support the timely availability and equitable deployment of medical countermeasures to affected and at-risk countries. As a minor update, today’s publication simply tracks factual changes to the indicators in our tracker, providing a regular checkpoint on progress toward the 100-day milestones.
These updates are intended to support the work of partners and key initiatives and are developed in consultation with implementing partners of the 100DM. We are open to feedback on the accuracy of our data, please get in touch (info@ippsecretariat.org) if you have information to share.
Previous updates:
Key developments since Day 15
Diagnostics:
Africa CDC, WHO, PATH, FIND, and Unitaid published an expression of interest (EOI) for manufacturers to participate in independent performance evaluations of Bundibugyo diagnostics across laboratory-based molecular kits, point-of-care molecular tests, and antigen based rapid diagnostic tests. The EOI was issued 5th June, with the Application deadline 11th June. Applications for 66 products are currently being reviewed in duplicate, and notification of short-listed candidates will take place on 19th June.
Africa CDC has secured 100% of KH Medical’s available production capacity for RADIONE diagnostics, with deployment of machines to double by end of June 2026 and technology transfer to Africa agreed.
WHO published formal submission instructions and requirements for manufacturers seeking EUL approval for in vitro diagnostics detecting Bundibugyo virus nucleic acids.
Therapeutics:
Gilead is providing remdesivir to support the Ugandan response under compassionate use and Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) frameworks for Bundibugyo virus disease treatment, and is preparing to support requests from the DRC, WHO, and regional and global partners for both remdesivir and obeldesivir, including support for planned clinical trials.
Clinical trials PARTNERS and EBO-PEP BUNDI remain expected to begin shortly. The PARTNERS protocol has received ethical and regulatory approval in the DRC. Import permits for remdesivir and MBP134 have been secured and shipment logistics are underway. Trial site selection is ongoing, and cold chain capacity has been assessed with identified gaps being addressed.
Vaccines:
BARDA has awarded funding to Public Health Vaccines for development of two rVSV-vectored Bundibugyo ebolavirus vaccine candidates: one developed in collaboration with the Public Health Agency of Canada, and a second, with CEPI co-funding Master Viral Seed stock generation based on research by Dr. Andrea Marzi and Dr. Heinz Feldmann at NIAID.
BARDA’s Rapid Response Partnership Vehicle (RRPV) has issued a request for project proposals for the BundiVx Programme to advance investigational BDBV vaccine candidates using the VSV platform.
CEPI has opened a second call for proposals supporting outbreak response data generation, including epidemiological modelling and outbreak analytics, as well as studies examining potential immune cross-protection from existing Zaire and Sudan ebolavirus vaccines.
CEPI has opened a Request for Information: Phase 1 Clinical Trial Capacity in Africa for BDBV Vaccines, seeking clinical research institutions across Africa (non-profit, for-profit, PDPs, government research organisations, academic institutions, intergovernmental organisations) capable of conducting rigorous ICH-GCP-compliant Phase I safety and immunogenicity trials for BDBV vaccine candidates (Deadline 26 June).
Cross-cutting:
WHO and Africa CDC jointly launched a Continental Preparedness and Response Plan to address the Bundibugyo ebolavirus outbreak. Operating under the principles of “One Team, One Plan, One Budget, and One Monitoring and Evaluation Framework”, the plan calls for USD$518 million to support national response and preparedness efforts.
A coordinated financial tracking mechanism has been launched by WHO and Africa CDC to track contributions against the response pillars outlined in the Continental Preparedness and Response Plan. The coordinated Financial Tracking Mechanism will also enhance transparency, accountability, and coordination of financing for the BVD response, and assess financing gaps across response pillars and countries, based on updated resource requirements and available funding.
The African Medicines Agency and African regulatory authorities are in collaboration with EMA’s Emergency Task Force to coordinate clinical trial designs and regulatory pathways for Bundibugyo countermeasures – the first emergency collaboration since AMA became operational.
Amref Health Africa launched Ebola preparedness responses in Western Equatoria State, South Sudan on 28 May and in northern Uganda on 2 June. The South Sudan activation, in a high-traffic border region where Amref manages Yambio State Hospital (the region’s only State Hospital, 24km from the DRC border), underscores the risk of further geographic spread beyond DRC and Uganda.
Status of DTVs
The medical countermeasures outlined in this section are not an exhaustive inventory of all products in development globally. Rather, they represent the candidates currently identified as leads for the response – those assessed by WHO TAG, actively discussed in partner coordination meeting, recommended for use by Africa CDC, and currently deployed or under evaluation. As new products emerge and existing candidates progress through development and evaluation, this landscape will continue to evolve.
Calls for Expression of Interest and Proposals
Diagnostics
WHO Emergency Use Listing (EUL) for nucleic acid detection tests:Manufacturers should submit expressions of interest through the EUL questionnaire. Formal submission instructions and requirements for manufacturers seeking EUL approval for in vitro diagnostics detecting Bundibugyo virus nucleic acids. [related to current response]
Therapeutics
BARDA’s Rapid Response Partnership Vehicle on filovirus small-molecule inhibitors: BARDA’s RRPV issued a request for information seeking AI-enabled discovery of broad-spectrum small-molecule inhibitors for filoviruses, including Bundibugyo virus (Deadline 17 June) [early stage]
EU Horizon call: Development of monoclonal antibody therapeutics for prevention and treatment of filoviral, nairoviral, phenuiviral, picornaviral and togaviral infections (Deadline 13 April 2027) [early stage]
Vaccines
CEPI Call for Proposals to advance early-stage BDBV vaccine candidates toward Phase 1 evaluation: Developers with scientifically robust candidates on credible pathways to clinical trials are encouraged to apply. (Deadline 19 June) [related to current response]
CEPI Call for Proposals to advance evidence generation for BDBV vaccine development through epidemiological modelling or immunological assessment of existing vaccine cross-protection. (Deadline 22 June) [related to current response]
CEPI request for information to identify Phase 1 clinical trial units across the African continent, for the possibility to conduct phase I clinical trials of Bundibugyo Ebolavirus vaccine candidates (Deadline 26 June). [related to current response]
BARDA’s RRPV request for project proposals for the BundiVx Programme to advance investigational BDBV vaccine candidates using the VSV platform (Deadline 26 June 2026).
Acknowledgements
We are grateful to the Pandemic Pact Programme, FIND, CEPI, PATH, IFPMA, Gilead, Roche, MSD, Unitaid, PANTHER Health, Intrepid Alliance, WHO, i-MCM-Net Secretariat, Wellcome, Institut Mérieux, Airfinity, IFPMA and Africa CDC for providing data, verification, and critical feedback to this tracker.
If you have additional updates or information you would like to see reflected in future iterations, please contact us at info@ippsecretariat.org.
Disclaimer for the Ebola Bundibugyo MCM Tools Tracker
Data shown in the tracker is not exhaustive. It prioritises candidates assessed by WHO TAG, actively discussed in partner coordination meetings and working groups, recommended by Africa CDC, and currently deployed or under evaluation. Additional products and updates will be integrated as they emerge and as existing candidates progress through development and evaluation.